Background: The SARS-CoV-2 pandemic has slowed down cancer prevention and treatment strategies; consequently, cancer patients are prioritized to get the COVID-19 vaccines. Being constantly threatened by a new outbreak, the dive within the immunogenicity response is of great value; nonetheless, evaluating the side effects of these vaccines on fragile patients will assure their adherence to the vaccination protocol. Objectives: This study sets out to investigate the adverse events reported about the vaccine according to its doses and types, and to compare the prevalence and severity of toxicities across two subgroups of cancer patients, those who received the injection during active therapy cycles, and those who have not started the therapy yet at vaccination time, moreover, this paper examines the will and commitment of this population to the vaccination schemes. Methods: This is an observational, retrospective, cohort study, in which we conducted a semi-constructed interview with 415 random solid cancer patients treated at the National Institute of Oncology in Morocco. The assessment of adverse events was carried out with a standardized scale. Results: Eleven months after the launch of the campaign, 75.2% of patients received at least one dose of the vaccine. Altogether, the analysis demonstrates a significant difference between the adverse effects reported post the second dose compared to the first one (p=0.004; odds ratio=2 [95% CI: 1.23 - 3.31]). Besides, the results indicate an increase in the rank of the severity of systemic events (p<0.001, r=0.28) after the second dose, but not for the local events (p=0.92, r=0.005). In the adjusted subgroup analysis, no effect was detected linking active therapy with the occurrence of toxicity (p=0.51, v=0.04) as well as with the level of severity reported after both; the first and second dose. Due to the fear of interactions with the therapy, we noticed a significant trend to delay the booster dose among the participants who completed the initial vaccine protocol. Conclusion: A considerable body of evidence exists to persuade cancer patients to take the Coronavirus vaccines, and to also follow their vaccination schemes under the supervision of their treating physicians.
Background: The SARS-CoV-2 pandemic has slowed down cancer prevention and treatment strategies; consequently, cancer patients are prioritized to get the COVID-19 vaccines. Being constantly threatened by a new outbreak, the dive within the immunogenicity response is of great value; nonetheless, evaluating the side effects of these vaccines on fragile patients will assure their adherence to the vaccination protocol. Objectives: This study sets out to investigate the adverse events reported about the vaccine according to its doses and types, and to compare the prevalence and severity of toxicities across two subgroups of cancer patients, those who received the injection during active therapy cycles, and those who have not started the therapy yet at vaccination time, moreover, this paper examines the will and commitment of this population to the vaccination schemes. Methods: This is an observational, retrospective, cohort study, in which we conducted a semi-constructed interview with 415 random solid cancer patients treated at the National Institute of Oncology in Morocco. The assessment of adverse events was carried out with a standardized scale. Results: Eleven months after the launch of the campaign, 75.2% of patients received at least one dose of the vaccine. Altogether, the analysis demonstrates a significant difference between the adverse effects reported post the second dose compared to the first one (p=0.004; odds ratio=2 [95% CI: 1.23 - 3.31]). Besides, the results indicate an increase in the rank of the severity of systemic events (p<0.001, r=0.28) after the second dose, but not for the local events (p=0.92, r=0.005). In the adjusted subgroup analysis, no effect was detected linking active therapy with the occurrence of toxicity (p=0.51, v=0.04) as well as with the level of severity reported after both; the first and second dose. Due to the fear of interactions with the therapy, we noticed a significant trend to delay the booster dose among the participants who completed the initial vaccine protocol. Conclusion: A considerable body of evidence exists to persuade cancer patients to take the Coronavirus vaccines, and to also follow their vaccination schemes under the supervision of their treating physicians.
Authors: J E Geddings; Y Hisada; Y Boulaftali; T M Getz; M Whelihan; R Fuentes; R Dee; B C Cooley; N S Key; A S Wolberg; W Bergmeier; N Mackman Journal: J Thromb Haemost Date: 2015-12-11 Impact factor: 5.824
Authors: Leticia Monin; Adam G Laing; Miguel Muñoz-Ruiz; Duncan R McKenzie; Irene Del Molino Del Barrio; Thanussuyah Alaguthurai; Clara Domingo-Vila; Thomas S Hayday; Carl Graham; Jeffrey Seow; Sultan Abdul-Jawad; Shraddha Kamdar; Elizabeth Harvey-Jones; Rosalind Graham; Jack Cooper; Muhammad Khan; Jennifer Vidler; Helen Kakkassery; Shubhankar Sinha; Richard Davis; Liane Dupont; Isaac Francos Quijorna; Charlotte O'Brien-Gore; Puay Ling Lee; Josephine Eum; Maria Conde Poole; Magdalene Joseph; Daniel Davies; Yin Wu; Angela Swampillai; Bernard V North; Ana Montes; Mark Harries; Anne Rigg; James Spicer; Michael H Malim; Paul Fields; Piers Patten; Francesca Di Rosa; Sophie Papa; Timothy Tree; Katie J Doores; Adrian C Hayday; Sheeba Irshad Journal: Lancet Oncol Date: 2021-04-27 Impact factor: 41.316
Authors: Joao V Horvat; Varadan Sevilimedu; Anton S Becker; Rocio Perez-Johnston; Randy Yeh; Kimberly N Feigin Journal: Eur Radiol Date: 2022-03-05 Impact factor: 7.034